FASEB J. Mp Biomedicals
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Published as doi: 10.1096/fj.08-120550.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow Buy
Right arrow All Versions of this Article:
fj.08-120550v1
23/3/751    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mukhopadhyay, A.
Right arrow Articles by Ogretmen, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mukhopadhyay, A.
Right arrow Articles by Ogretmen, B.
(The FASEB Journal. 2009;23:751-763.)
© 2009 FASEB

Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signaling

Archana Mukhopadhyay*,{dagger}, Sahar A. Saddoughi*,{dagger}, Pengfei Song*,{dagger}, Iyad Sultan*,{dagger},1, Suriyan Ponnusamy*,{dagger}, Can E. Senkal*,{dagger}, Christopher F. Snook*, Hugh K. Arnold{ddagger}, Rosalie C. Sears{ddagger}, Yusuf A. Hannun*,{dagger} and Besim Ogretmen*,{dagger},2

* Department of Biochemistry and Molecular Biology and

{dagger} Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, USA; and

{ddagger} Department of Molecular Medical Genetics, Oregon Health and Sciences University, Portland, Oregon, USA

2Correspondence: Hollings Cancer Center, Medical University of South Carolina, 86 Jonathan Lucas St., Charleston, SC 29425, USA. E-mail: ogretmen{at}musc.edu

In this study, the inhibitor 2 of protein phosphatase 2A (I2PP2A) was identified in vitro and in situ as a ceramide-binding protein, which exhibits stereoisomer specificity and fatty acid chain length preference. Site- directed mutagenesis coupled with structural details of I2PP2A suggested that VIK 207-209 residues localized on helix 7 are important for ceramide binding and single mutation of K209D altered this interaction. Notably, I2PP2A-ceramide binding decreased the association between PP2A and the inhibitor, preventing the inhibition of PP2A activity in vitro. In addition, studies in A549 human lung cancer cells revealed that ceramide mediates c-Myc degradation via its PP2A-dependent dephosphorylation at S62, and treatment with okadaic acid and expression of c-Myc mutants with S62A or S62D conversions resulted in resistance to ceramide-mediated degradation. Importantly, whereas down-regulation of I2PP2A enhanced PP2A-mediated c-Myc degradation in response to ceramide, ectopic expression of wild-type I2PP2A but not of its K209D mutant protected this degradation in A549 cells. Moreover, expression of wild-type I2PP2A prevented the growth-inhibitory effects of ceramide both against A549 cells and xenograft-driven tumors in situ and in vivo compared with that in controls. Thus, these results suggest that direct interaction of I2PP2A with ceramide plays important biological roles via the regulation of PP2A activity and signaling, which in turn control ceramide-mediated degradation of c-Myc and antiproliferation.—Mukhopadhyay, A., Saddoughi, S. A., Song, P., Sultan, I., Ponnusamy, S., Senkal, C. E., Snook, C. F., Arnold, H. K., Sears, R. C., Hannun, Y. A., Ogretmen, B. Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signaling.


Key Words: bioactive lipids • c-Myc degradation




This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
J. L. McConnell and B. E. Wadzinski
Targeting Protein Serine/Threonine Phosphatases for Drug Development
Mol. Pharmacol., June 1, 2009; 75(6): 1249 - 1261.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by The Federation of American Societies for Experimental Biology.